Adcetris is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Adcetris is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameAdcetris
Authorized genericbrentuximab vedotin
Regular genericbrentuximab vedotin
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Adcetris?
The original
–
–

Brand nameThe maker’s card

Pfizer Oncology Together Co-Pay Savings Program for Injectables

Savings card from Pfizer

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

The card takes up to $15,000 a year off your co-pay.

Sign up on pfizercopay.com 

Or call 1-800-555-4820.

In the maker’s words

“as little as $0 per administered dose.”

From the maker’s offer on pfizercopay.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Adcetris itself, from the same company, sold without the brand name, and usually for less. For now Adcetris is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Adcetris is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of:

  • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
  • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
  • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
  • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone.
  • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.
  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.

Source: the FDA label for Adcetris (SEAGEN INC.), November 11, 2025. Full label on DailyMed 

Good to know